CCCC (STOCKS)
C4 Therapeutics, Inc.
$2.737700
+0.202700 (+8.00%)
Prev close: $2.535000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Andrew J. Hirsch
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $269.32M
- Employees
- 110
- P/E (TTM)
- -2.03
- P/B (TTM)
- 0.96
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.18 | $-0.31 | +0.1298 | +41.90% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.41 | -0.0257 | -6.20% |
|
Jun 2025 (Q2)
|
$-0.37 | $-0.39 | +0.0217 | +5.54% |
|
Mar 2025 (Q1)
|
$-0.37 | $-0.46 | +0.0890 | +19.39% |
Financial Statements
| Revenues | $35.95M |
| Benefits Costs and Expenses | $140.82M |
| Costs And Expenses | $140.82M |
| Nonoperating Income/Loss | $10.35M |
| Operating Expenses | $151.17M |
| Depreciation and Amortization | $1.96M |
| Research and Development | $104.24M |
| Other Operating Expenses | $44.97M |
| Operating Income/Loss | -$115.22M |
| Income/Loss From Continuing Operations After Tax | -$104.99M |
| Income/Loss From Continuing Operations Before Tax | -$104.87M |
| Income Tax Expense/Benefit | $121.00K |
| Income Tax Expense/Benefit, Current | $121.00K |
| Net Income/Loss | -$104.99M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$104.99M |
| Net Income/Loss Available To Common Stockholders, Basic | -$104.99M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.27 |
| Diluted Earnings Per Share | -$1.27 |
| Basic Average Shares | 82,894,459 |
| Diluted Average Shares | 82,894,459 |
| Assets | $359.08M |
| Current Assets | $258.11M |
| Cash | $297.10M |
| Accounts Receivable | $2.40M |
| Noncurrent Assets | $100.97M |
| Fixed Assets | $4.74M |
| Other Non-current Assets | $96.22M |
| Liabilities | $102.49M |
| Current Liabilities | $33.03M |
| Accounts Payable | $858.00K |
| Other Current Liabilities | $32.17M |
| Noncurrent Liabilities | $69.46M |
| Equity | $256.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $256.59M |
| Liabilities And Equity | $359.08M |
| Net Cash Flow From Operating Activities | -$98.69M |
| Net Cash Flow From Operating Activities, Continuing | -$98.69M |
| Net Cash Flow From Investing Activities | -$8.60M |
| Net Cash Flow From Investing Activities, Continuing | -$8.60M |
| Net Cash Flow From Financing Activities | $126.40M |
| Net Cash Flow From Financing Activities, Continuing | $126.40M |
| Net Cash Flow | $19.10M |
| Net Cash Flow, Continuing | $19.10M |
| Comprehensive Income/Loss | -$105.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$105.00M |
| Other Comprehensive Income/Loss | -$105.00M |